AOD-9604 dosage guide: research protocols, safety, and reconstitution

This AOD-9604 dosage guide explains what the published human and animal research actually used, why online protocols often differ, and how researchers think about vial math without pretending this peptide is an approved weight-loss drug.

What AOD-9604 is, and what it is not

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone. The research idea was simple: keep interest in lipid metabolism without triggering the broader growth-promoting effects associated with full growth hormone exposure.

The early literature around hGH fragment 177-191 found antilipogenic activity in experimental models. Heffernan and colleagues later reported that an orally administered synthetic hGH fragment affected lipid metabolism in a 2000 paper in the American Journal of Physiology-Endocrinology and Metabolism.

But the clinical story is more restrained than peptide forums make it sound. AOD-9604 is not semaglutide, tirzepatide, retatrutide, or tesamorelin. It is also not a SARM. It sits in a narrow research category: a growth hormone fragment studied for fat metabolism.

If the goal is to compare it against stronger weight-management compounds, start with peptides for weight loss, the ranked weight-loss peptide guide, and the main AOD-9604 peptide research overview.

AOD-9604 dosage guide from published research

The most useful human dosing reference is the obesity trial program, not a social media protocol card. A 2013 safety review in the Journal of Endocrinology and Metabolism describes a randomized study with 502 clinically obese subjects after screening and enrollment. Participants received placebo or 0.25 mg, 0.5 mg, or 1 mg of AOD-9604 daily for 24 weeks.

Another trial summary reported that a 12-week phase II study used 1 mg oral AOD-9604 and found weight-loss and glucose-tolerance signals versus placebo. The catch: later development did not turn AOD-9604 into an approved obesity medication.

That matters. A dosage guide should separate what was tested from what is proven. A studied dose can tell researchers where the literature has been. It does not create permission for unsupervised use.

AOD-9604 dosage guide for reconstitution math

Most research AOD-9604 vials are sold lyophilized. That means the number printed on the vial is total peptide mass, not the amount in each syringe unit after mixing.

So the practical math starts with three inputs: vial strength, bacteriostatic water volume, and target mcg measurement. There is no way around that.

Example: if a 5 mg vial is mixed with 2 mL of bacteriostatic water, the concentration is 2.5 mg/mL. Since 2.5 mg equals 2,500 mcg, a 0.1 mL draw equals 250 mcg.

That example is for arithmetic only. Researchers should run their own vial numbers through the PeptidePick reconstitution calculator and review how to mix peptides before handling sterile research materials.

Common vial math examples

Safety, legality, and what the evidence does not prove

The AOD-9604 safety literature is more developed than many fringe peptides, but it is still limited. The 2013 human safety review described placebo-like tolerability in the clinical program and summarized the 24-week obesity trial exposure.

That is useful. It is not the same as broad post-market safety surveillance for an approved medicine.

The FDA has not approved AOD-9604 for weight loss or any other therapeutic indication. In sport, AOD-9604 has also drawn anti-doping attention because it is related to growth hormone fragment research and non-approved peptide use.

The biggest uncertainty is not whether the molecule has a plausible mechanism. It does. The harder question is whether that mechanism translates into meaningful body-composition results for real people outside controlled research. The evidence is mixed enough that confident claims should raise suspicion.

For storage and sterile handling context, see how to store peptides, bacteriostatic water for peptides, and peptide injection site rotation.

Timing, cycle length, and research design

Most AOD-9604 protocol pages jump straight to daily measurements. That is backwards. A clean research design starts with the question being tested: fat oxidation, body weight, glucose tolerance, appetite, or a sourcing comparison.

The published human obesity program used daily administration over weeks, including the 24-week trial described in the safety review. That gives researchers a time horizon to study, but it should not be read as proof that every project needs a long cycle.

Short trials can miss slow body-composition signals. Long trials create more room for diet changes, training changes, adherence problems, sleep changes, and measurement noise. So there is a tradeoff.

For lab notebooks, the most useful schedule is boring and consistent. Record the vial lot, reconstitution date, storage condition, target measurement, actual measurement, and any visible change in the solution. If the project also tracks weight or body composition, the measurement method should stay the same every time.

AOD-9604 should not be judged by scale weight alone. If a subject changes sodium intake, carbohydrate intake, or training volume, water shifts can hide the actual signal. That is one reason controlled trials matter more than before-and-after photos.

Researchers comparing AOD-9604 with GLP-1 compounds should avoid direct dose comparisons. A 250 mcg peptide measurement and a semaglutide dose are not interchangeable data points. The compounds act through different pathways and have different approval histories.

Side effects and risk controls in AOD-9604 research

Human safety summaries have generally described AOD-9604 as well tolerated in the studied obesity populations. Reported adverse-event patterns did not create the kind of safety signal that full growth hormone exposure can raise, such as broad growth-promoting activity.

Still, that sentence can be misused. Well tolerated in a trial does not mean risk-free in an uncontrolled setting. It also does not guarantee quality when a vial comes from a research vendor rather than a regulated pharmacy.

The most realistic risk controls are simple. Use documented vendors, check COAs, avoid mystery blends, confirm the compound name, and reject vials with damaged seals or unclear labels. If sterility matters to the research setup, sterile handling and storage are not optional details.

Another overlooked issue is expectation drift. AOD-9604 is often marketed near stronger weight-loss drugs, so readers expect GLP-1-like results. The evidence does not support that level of confidence. The better position is cautious: plausible mechanism, some human exposure data, and no FDA-approved obesity indication.

Researchers who want an approved medical weight-loss option should talk to a licensed clinician about regulated therapies. Research peptides from vendors are not a substitute for prescribed medication.

For that reason, AOD-9604 research works best when the outcome measures are chosen before the vial is mixed. Changing endpoints after results appear makes weak data look cleaner than it is.

Where sourcing fits in an AOD-9604 dosage guide

Dosage math is only one part of research quality. If the vial is mislabeled, degraded, underfilled, or contaminated, the calculator can be perfect and the project can still fail.

Good sourcing standards usually include third-party testing, clear lot numbers, visible COAs, cold-chain awareness where relevant, and responsive support. PeptidePick maintains a broader best peptide companies guide for comparing vendors without turning every article into a store page.

For AOD-9604, the practical comparison is usually between single-compound suppliers and broader weight-management catalogs. GLP-1 articles such as the tirzepatide dosage guide, retatrutide dosage protocol, and natural Ozempic alternatives can help frame where AOD-9604 sits.

Research notes and source points

• Wu and Ng reported antilipogenic action from the synthetic C-terminal hGH 177-191 sequence in Biochemical and Molecular Biology International in 1993.
• Heffernan and colleagues reported lipid-metabolism effects from oral administration of a synthetic hGH fragment in American Journal of Physiology-Endocrinology and Metabolism in 2000.
• A mouse study indexed in PubMed reported reduced body weight gain and increased fat oxidation after chronic treatment with hGH or a modified C-terminal fragment.
• Wilding's 2004 review described AOD-9604 as a Metabolic Pharmaceuticals obesity-development candidate, with phase IIa work underway by early 2002.
• The 2013 safety review by Stier summarized human tolerability data and described a 24-week trial with 0.25 mg, 0.5 mg, and 1 mg daily arms.

Related articles

• AOD-9604 peptide research guide
• Peptides for weight loss
• Best peptides for weight loss ranked
• Free peptide reconstitution calculator
• How to reconstitute peptides
• Peptide cycle length guide

FAQ

What is the typical AOD-9604 dosage discussed in research?

Human obesity research described oral daily doses of 0.25 mg, 0.5 mg, and 1 mg. Research-vendor discussions often use mcg-based vial math, but those are not approved clinical instructions.

Is AOD-9604 FDA approved?

No. AOD-9604 is not FDA approved for weight loss, fat loss, metabolic disease, or any therapeutic use.

How do you calculate AOD-9604 after reconstitution?

Divide total peptide mass by the water volume to get concentration. Then convert mg to mcg and calculate the measurement volume. The PeptidePick calculator handles this arithmetic.

Is AOD-9604 the same as hGH 176-191?

They are closely related in the way people discuss growth hormone fragment research, but naming can vary by vendor and paper. Always verify the exact compound and sequence from the certificate of analysis.

Does AOD-9604 work like semaglutide?

No. Semaglutide is a GLP-1 receptor agonist with FDA-approved uses. AOD-9604 is a growth hormone fragment research peptide with a different mechanism and a much weaker approval profile.

Can AOD-9604 be stacked with other peptides?

Stacking is common in online discussions, but it also adds confounding variables. For research design, single-compound testing is cleaner before comparing combinations.